Regarding Menomune (MPSV4), what is the re-vaccination term or time frame?
Revaccination might be indicated for persons previously vaccinated with MPSV4 who remain at increased risk for infection (e.g., persons residing in areas in which disease is epidemic), particularly children who were first vaccinated at age <4 years. Such children should be considered for revaccination after 2–3 years if they remain at increased risk. Although the need for revaccination among adults and older children after receiving MPSV4 has not been determined, antibody levels decline rapidly after 2–3 years, and, if indications still exist for vaccination, revaccination might be considered after 5 years. MCV4 is recommended for revaccination of persons aged 11–55 years; however, use of MSPV4 is acceptable. NOTE: Continued attendance at college is NOT an indication for revaccination.
